Exchange: NASDAQ·Updated 10:45 PM EDT
News
all
press releases
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG
BTIG upgraded the stock to ‘Buy’ from ‘Neutral’ after Outlook Therapeutics received regulatory approval for its wet AMD therapy.
Stocktwits
More News
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus
Despite the futures rebound, retail investors remain cautious. Stocktwits data showed retail sentiment is ‘bearish’ on SPY and QQQ.
Stocktwits
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside
Outlook expects a U.S. launch before year-end and anticipates 12 years of market exclusivity.
Stocktwits
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab
LYTENAVA is now the first and only FDA-approved version of the drug bevacizumab specifically made for injection into the eye to treat wet age-related macular degeneration.
Stocktwits
OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’
After two rejections, retail investors are hopeful the FDA will approve Outlook Therapeutics’ Lytenava for the treatment of wet AMD.
Stocktwits
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Zacks
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.read more...
Benzinga
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision
The agency will now decide whether to approve the drug by July 29, 2026.
Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal
A decision on the resubmitted application is expected within 60 days of the FDA’s receipt of it, the company said.
Stocktwits
OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record
Outlook Therapeutics wins appeal following formal dispute resolution process for LYTENAVA.
Stocktwits
<
1
2
>

Advertisement|Remove ads.